echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui's entry of 1.5 billion original anesthetic drugs is hit again

    Hengrui's entry of 1.5 billion original anesthetic drugs is hit again

    • Last Update: 2021-08-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Wonderful content

    Wonderful content

    A few days ago, Hengrui Medicine issued an announcement stating that the company has obtained approval for its imitation of Propofol medium/long-chain fat emulsion injections for production of 4 categories, and it is deemed to have been reviewed
    .


    Up to now, the company has invested approximately 21.


    Basic situation of drugs

    Propofol medium/long-chain fat emulsion injection is a fast-acting short-acting general intravenous anesthetic.
    It was developed by Fresenius Kabi and has been approved for marketing in Germany, Austria and other countries
    .


    In February 2007, Fresenius Kabi was approved for listing in China


    Source: One-click search on Mi Nei.
    com

    According to data from Menet.
    com, in 2020, China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal propofol medium/long-chain fat emulsion injection sales exceeded 1.
    5 billion yuan.
    Among them, Fresenius Kabi has the largest market share, exceeding 50%; Sichuan Guorui Pharmaceutical and Guangdong Jiabo Pharmaceutical rank second and third respectively
    .

    Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database

    Up to now, there are 8 propofol medium/long-chain fat emulsion injection manufacturers, of which 6 domestic companies have been evaluated.
    Sichuan Guorui Pharmaceutical and Guangdong Jiabo Pharmaceutical have been approved as supplementary applications, and Sichuan Kelun Pharmaceutical Industry, Jiangsu Yingke Biopharmaceuticals, Yangtze River Pharmaceuticals, and Jiangsu Hengrui Pharmaceuticals have been approved in 4 categories of imitations, which are deemed to have been reviewed
    .


    In addition, 7 companies including Yichang Renfu Pharmaceutical Co.


    Source: Listed company announcement, Mi Nei.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.